March 2019

WHK Interns Help Elementary School Students Learn to Love Science

It’s half an hour to showtime in the spacious, sun-filled atrium. Glance upward and you can’t miss the painted five-foot-tall black paw print and the inscription “Panther Pride” along the open staircase’s tallest yellow wall. Clustered around the lobby, 20 presenters are steeling their nerves as best they can: pacing, fidgeting, rehearsing. Pressure to perform aside, it’s a decidedly casual event, evidenced by several shoelaces that need tying.

In This CCR Lab, Mentorship Yields Tremendous Results

When Joshua Yu became a semifinalist in the 2019 Regeneron Science Talent Search, he continued a tradition he didn’t even know existed. A Werner H. Kirsten (WHK) intern, Yu is the latest in a long line of students hailing from Nadya Tarasova, Ph.D.’s lab to make the semifinals in the Regeneron competition, which bills itself as the nation’s oldest and most prestigious science and math competition for high school seniors.

Inside the Scientific Arsenal: The High-Speed Racetrack That Can Make Proteins Explode

Ben Orsburn, Ph.D., stood in the middle of a 180-square-foot laboratory, speaking over the white noise that flooded the room. The source of the din—large, desk-sized objects called mass spectrometers—filled nearby rows of lab benches. Orsburn pointed to one along the periphery of the room, a white-and-black box with the words “Orbitrap Fusion” emblazoned on the front in small blue text.

The Intellectual Property and Strategic Agreements Office Moves FNL Technologies Forward

Technology transfer at national laboratories presents challenges, and the Frederick National Laboratory is no exception. But that hasn’t stopped Claudia Haywood, Tom Sova, and Candice Garner-Groves from notching a series of accomplishments that span their tenure at FNL.

Anticancer Antibody Receives First Funds for Trial in Leukemia Patients

An anti-leukemia compound identified at NCI at Frederick is one step closer to entering clinical trials in humans thanks to a $4.2-million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). CPRIT recently gave the funds to Allterum Therapeutics, Inc., a Texas-based biotechnology startup company created to manufacture the compound, Allterum, and advance it to human trials. The grant represents the first step in the multi-million-dollar process to bring Allterum to the clinic.

At Winter Poster Session, Eager Student Interns Present Research for the First Time

Butterflies in the stomach, a cold sweat, a feeling of dread: most of us know and fear the nervousness that accompanies public speaking. It was a pleasant surprise, therefore, to see apparently fearless Werner H. Kirsten student interns speak at NCI at Frederick’s WHK Student Intern Program Winter Poster Session. The event gave the dozen or so high school students a chance to present their hard-won research to NCI at Frederick staff. For many, it was their first time speaking about their projects in public.

“Something Just Clicked”: Partnership Pushes New Class of Cancer Drug Toward Human Trials

Serguei Kozlov, Ph.D., doesn’t recall if it was he who first contacted clinician Udo Rudloff, M.D., Ph.D., or Rudloff who contacted him. He just knows that their resulting two-year collaboration, which recently moved a first-in-class drug for metastatic cancer toward clinical trials, is one of the best he’s ever had.